Recursion acquires two AI-based drug discovery companies in $87.5M deal
AI drug developer Recursion Pharmaceuticals has brought two more AI-focused companies with their own discovery platforms under its wing in an acquisition worth $87.5 million, the company announced today.
Recursion is buying both companies, Cyclica and Valence, mostly in equity. The deals come as insiders predict a surge in biotech M&A — with smaller players, not just Big Pharma, ready to jump on tuck-in acquisitions of even smaller companies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.